Receptor Recognition of and Immune Intracellular Pathways for *Veillonella parvula* Lipopolysaccharide

Giovanni Matera, Valentina Muto, Maria Vinci, Emilia Zicca, Shahla Abdollahi-Roodsaz, Frank L. van de Veerdonk, Bart-Jan Kullberg, Maria Carla Liberto, Jos W. M. van der Meer, Alfredo Focà, Mihai G. Netea and Leo A. B. Joosten


Published Ahead of Print 14 October 2009.

Updated information and services can be found at: http://cvi.asm.org/content/16/12/1804

**REFERENCES**

*These include:*

This article cites 38 articles, 18 of which can be accessed free at: http://cvi.asm.org/content/16/12/1804#ref-list-1

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), [more »](http://cvi.asm.org/content/16/12/1804#ref-list-1)

Information about commercial reprint orders: [http://journals.asm.org/site/misc/reprints.xhtml](http://journals.asm.org/site/misc/reprints.xhtml)

To subscribe to to another ASM Journal go to: [http://journals.asm.org/site/subscriptions/](http://journals.asm.org/site/subscriptions/)
Receptor Recognition of and Immune Intracellular Pathways for *Veillonella parvula* Lipopolysaccharide

Giovanni Matera,1 Valentina Muto,1 Maria Vinci,1 Emilia Zicca,1 Shahla Abdollahi-Roodsaz,4 Frank L. van de Veerdonk,2,3 Bart-Jan Kullberg,2,3 Maria Carla Liberto,1 Jos W. M. van der Meer,2,3 Alfredo Foca,3 Mihai G. Netea,2,3 and Leo A. B. Joosten2,3*

Institute of Microbiology, Department of Medical Sciences, University of Cantanzaro, Cantanzaro, Italy,1 and Department of Medicine,2 Nijmegen Institute for Infection, Inflammation and Immunity,3 and Rheumatology Research & Advanced Therapeutics, Department of Rheumatology,4 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Received 24 July 2009/Returned for modification 18 August 2009/Accepted 5 October 2009

*Veillonella parvula* is an anaerobic gram-negative coccus that is part of the normal flora of the animal and human mouth and gastrointestinal and genitourinary tracts. Oral *V. parvula* is involved in the development of early periodontal disease as well as different types of serious infections. Present data on molecular mechanisms responsible for innate immune response against *Veillonella* are very scanty. The aim of this study was to investigate the Toll-like receptor (TLR) pathways responsible for *V. parvula* lipopolysaccharide (LPS) and to identify the intracellular pathways induced by this recognition. *V. parvula* LPS stimulated tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) release in human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. Pretreatment of cells with a TLR4 antagonist significantly reduced TNF-α and IL-6 production in PBMC stimulated with either *Veillonella* or *Escherichia coli* LPS. However, *V. parvula* LPS was 10- to 100-fold less active than *E. coli* LPS for cytokine induction. TNF-α, IL-1β, IL-6, and IL-10 were released in wild-type and TLR2−/−, but not TLR4−/−, mouse macrophage cultures. *V. parvula* LPS was able to activate the human PBMC p38 mitogen-activated protein kinase (MAPK). A specific p38 MAPK inhibitor strongly inhibited *V. parvula* LPS-induced TNF-α, IL-1β, IL-6, and IL-10. In conclusion, *V. parvula* LPS is able to induce cytokine production in both human and murine in vitro models, although it is less effective than *Enterobacteriaceae* LPS. *V. parvula* LPS-stimulated cytokine induction, as well as p38 MAPK activation, are TLR4-dependent features.

*Veillonella* organisms are small, nonfermentative, strictly anaerobic, gram-negative coccii which form part of the normal flora of the oral, genitourinary, respiratory, and intestinal tracts of humans and animals (10). The genus *Veillonella* was first isolated by Veillon and Zubler in 1898 and currently consists of eight species (28).

*Veillonella* species have been reported as causes of serious infections, including meningitis (6), osteomyelitis and discitis (7, 28), prosthetic joint infection (26), and acute and chronic pleuropulmonary infection (33).

Risk factors for *Veillonella* infection include periodontal disease, immunodeficiency, intravenous drug use, and premature birth (28). *V. parvula* is an important pathogen implicated in periodontitis and other dental infections (3, 18), and it is one of the most common anaerobic pathogens in chronic maxillary sinusitis and deep neck infections (9, 37). *V. parvula* has also been reported as a pathogen for osteomyelitis (34) and abscessed orchiepididymitis with sepsis (4). Endovascular infections reportedly may range from bacteremia to severe endocarditis and fatal cases of sepsis (8, 14, 25).

Lipopolysaccharides (LPS) are major pathogenic factors of gram-negative bacteria. LPS from aerobic and facultative bacteria have been extensively studied (5). On the contrary, little is known regarding the biological activity of LPS from anaerobic microorganisms such as *Veillonella* (10, 24, 29, 32). In addition, little is known about cellular and molecular mechanisms responsible for innate immune response against *V. parvula*, as well as for inflammatory reactions leading to severe periodontitis or sinusitis. Toll-like receptors (TLRs) recognize microbial compounds (36) and trigger the inflammatory and immune responses against pathogens. Immunohistochemical localization of TLR2 and TLR4 in gingival tissue of periodontitis patients has been reported (30). In mammals, engagement of TLRs by LPS results in the recruitment of cytoplasmic signaling molecules (12, 36), which eventually activates mitogen-activated protein kinases (MAPKs), including p38, JNK, and extracellular signal-regulated kinase (ERK). MAPK activation leads to cytokine release (2).

However, the interaction between oral *V. parvula* LPS and TLRs has not been directly studied yet. The aim of this study was to investigate the potential role of TLR2 and TLR4 for the recognition of *Veillonella parvula* LPS in both human peripheral blood mononuclear cells (PBMC) and in TLR2 and TLR4 knockout (KO) mouse macrophages, as well as the intracellular kinase signaling pathways induced after challenge of monocytes with *Veillonella parvula* LPS.

**MATERIALS AND METHODS**

*Veillonella parvula* culture and LPS purification. *V. parvula* ATCC 10790 (American Type Culture Collection, Rockville, MD) was grown anaerobically in modified lactate broth at 37°C. After *V. parvula* reached the early stationary phase (about 40 h of incubation), bacterial cells were harvested by centrifugation.
Isolation of peripheral blood mononuclear cells and stimulation of cytokine production.

Isolation of PBMC was performed as described elsewhere (1), with minor modifications. All volunteers signed an informed consent form, according to the institutional guidelines and procedures. A total of 5 × 10⁸ PBMC in a 100-μl volume were added to round-bottom 96-well plates (Greiner) and incubated with either 100 μl of culture medium or the various stimuli: highly purified Veillonella LPS (1 to 10 ng/ml), highly purified E. coli LPS (1 ng/ml), or Pam3Cys (10 μg/ml; EMC Microcollections). In some experimental sets, cells were pretreated with or without double-extracted Bartonella quintana LPS (1 μg/ml, a TLR4 agonist) (31), 30 min before treatment with V. parvula LPS (100 ng/ml). Specific signal transduction inhibitors of p38 MAPK (SB202190; 25 μM), ERK1/2 (U0126; 25 μM), JNK1/2/3 kinase (SP600125; 25 μM) (all inhibitors purchased from Superarray Bioscience Corporation, Bethesda, MD) were added to the cultures for 45 min prior to addition of Veillonella LPS. All unstimulated and control samples received an equal amount of inhibitor solvent, dimethyl sulfoxide (0.1% [vol/vol]). After 24 h of culture, the supernatants were collected, centrifuged at 1,200 rpm, and stored at −80°C until assayed.

Isolation of peritoneal macrophages and stimulation of cytokine production.

For isolation of mouse peritoneal macrophages and spleen cells, groups of five mice were injected with 4 ml of sterile phosphate-buffered saline containing 3% sodium citrate. After washing, the spleens were removed and minced, and the resulting cell suspensions were recultured twice with phenol-water and recentrifuged at 105,000 g for 10 min at 4°C. The supernatants were dialyzed against 20 liters of distilled water at 4°C. The crude LPS was lyophilized and then dissolved in distilled water and centrifuged once at 105,000 × g for 3 h at 4°C. The LPS solution was then added to RPMI 1640 medium containing 10 mM HEPES, 2 mM L-glutamine, 100 μg/ml gentamicin, and 2% fresh mouse plasma (culture medium). Cells were cultured in 96-well microtiter plates (Greiner, Alphen, The Netherlands) at 10⁴ cells per well, in a final volume of 200 μl. The cells were stimulated with either control medium or highly purified Veillonella LPS (1 μg/ml), highly purified E. coli LPS (1 ng/ml), or Pam3Cys (10 ng/ml). After 24 h of incubation at 37°C, the plates were centrifuged (500 × g, 10 min), and the supernatant and cell lysate (three freeze-thaw cycles) were collected and stored at −80°C until cytokine assays were performed.

Cytokine determinations. Human tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), IL-6, and IL-10 were measured by using either specific or nonhost-specific ELISAs. Human PBMC were stimulated with a dose of purified Veillonella LPS (1 ng/ml), or Pam3Cys (1 μg/ml), IL-6, and DNase (Sigma) at 20 μg/ml each. After 2 h of incubation at 37°C, the solution was centrifuged at 105,000 × g for 4 h at 4°C. The final pellet was dissolved in distilled water, lyophilized, and stored at −20°C as once-purified LPS. Double-step-purified LPS (repurified LPS) was obtained following the method described by Hirschfeld et al. (17).

RESULTS

V. parvula LPS is a weak stimulator of cytokine production in human PBMC. Following stimulation with increasing amounts of V. parvula LPS (1 to 100 ng/ml), human PBMC released TNF-α and IL-6 in a dose-related fashion. The highest concentration of V. parvula LPS used (100 ng/ml) released an amount of the above cytokines that was comparable to that produced by 1 ng/ml of the reference E. coli LPS (Fig. 1A and B).

A TLR4 antagonist blocks V. parvula LPS-induced cytokine production. When human PBMC were pretreated with a TLR4 antagonist (B. quintana LPS at 1 μg/ml), the release of TNF-α and IL-6 following stimulation with V. parvula LPS (1 to 100 ng/ml) was reduced compared to Staphylococcus aureus LPS (1 μg/ml) and Pam3Cys (1 μg/ml) stimulation. Statistical analysis of the data are expressed as mean ± standard errors of the means unless indicated otherwise. Differences between experimental groups were tested using the Mann-Whitney U-test, performed using GraphPad Prism 4 software. P values of 0.05 or less were considered significant.
ng/ml), as well as with 1 ng/ml of the reference E. coli LPS, was strongly inhibited (Fig. 2A and B).

**TLR4 is the major receptor for V. parvula LPS-induced cytokine production in mice.** Resident peritoneal macrophages were harvested from TLR2−/− and TLR4−/− mice and their control littermates and stimulated in vitro with either control medium or highly purified Veillonella LPS (1 μg/ml), highly purified E. coli LPS (1 ng/ml), or Pam3Cys (10 ng/ml). The three stimuli used were able to produce a cytokine release substantially higher than medium alone in control macrophage cultures. Although Veillonella LPS caused a significant release of cytokines in the macrophages from TLR2−/− mice, it was not able to induce a relevant release of cytokines among the macrophages from TLR4−/− mice (Fig. 3A and B and 4A and B).

**Veillonella-induced activation of p38 MAPK, which mediates cytokine production.** V. parvula LPS was able to activate the human PBMC p38 MAPK after 60 minutes of incubation. When B. quintana double-purified LPS was used to inhibit TLR4 on PBMC, activation of p38 MAPK was hardly inhibited after 60 minutes (Fig. 5A).

The activation of JNK and ERK1/2 after the V. parvula LPS stimulus was very inconsistently observed regardless of the time point considered (15, 30, and 60 min) (data not shown). In line with these data, a p38 MAPK inhibitor strongly reduced cytokine production induced by V. parvula LPS (Fig. 5B and C). Similar results were observed with an inhibitor of JNK kinase, while inhibition of ERK had a more modest effect (Fig. 5B and C).

**DISCUSSION**

In the present paper we demonstrate that V. parvula LPS is recognized by TLR4 in both humans and mice and that the activation of MAP kinases plays an important role in V. parvula LPS-stimulated human PBMC signaling.
Previous studies on the in vitro and in vivo activities of the LPS from *Veillonella parvula* demonstrated that such an endotoxin has biological effects comparable to enterobacterial LPS (10, 29). Earlier studies reported on fibroblast collagenase-inducing PBMC cytokines stimulated by *Veillonella* spp. LPS; however, such cytokines were not directly evaluated (16). Formalin-killed *V. parvula* has been demonstrated to induce the release of IL-1β in human blood monocytes at levels comparable to those released by *Porphyromonas gingivalis*, *Bacteroides forsythus*, and *Prevotella intermedia* (27). More recent investigations showed that the concentrations of TNF-α and IL-10 released from umbilical cord and adult mononuclear cells following in vitro challenge with UV-killed *V. parvula* were comparable or even higher than cytokine concentrations evaluated in *Pseudomonas aeruginosa*- and *E. coli*-stimulated cord and adult cells (19).

The lower cytokine production of PBMC induced by *Veil-
In one study treatment of dendritic cells with an anti-TLR4 antagonist decreased cytokine production induced by UV-treated *V. parvula* (20), but the nature of the *Veillonella* ligand recognized by TLR4 was not identified.

Similarly, TLR2- and TLR4-transfected human embryonic kidney cells responded to sonicated *Veillonella* bacteria stimulation (21). In both these studies, *Veillonella* seemed to stimulate both TLR4 and TLR2. However, the bacterial product responsible for the TLR engagement was not addressed, and the models used were only from murine species. In the present study, we demonstrate that *V. parvula* LPS is recognized by TLR4 in both human and murine cells, and we show the MAPK role in *Veillonella* LPS-stimulated human PBMC signaling.

*V. parvula* has been implicated in both dental/periodontal diseases (3, 18) and joint disorders (26). Periodontal disease and rheumatoid arthritis have remarkably similar inflammatory mediator profiles (22). Within periodontal lesions, activated monocytes, macrophages, and fibroblasts produce cytokines, such as TNF-α, IL-1β, and IL-6, which have been found to be significantly elevated in diseased periodontal sites compared with healthy or inactive sites (11). These cytokines orchestrate the cascade of destructive events that occur in the periodontal tissues and trigger the production of an array of inflammatory enzymes and mediators, resulting in irreversible hard and soft tissue damage (15). By exploiting an in vitro model of periodontal diseases, it has been found that upregulation of IL-6 by lipopolysaccharide treatment is TLR4 dependent. This pattern of gene expression indicates that pathogens may trigger TLR4 signaling and cause periodontitis (35). Therefore, our present findings may have sound clinical impact. Moreover, due to the similarity of pathogenesis between periodontitis and rheumatoid arthritis, antagonists of TLR4, as well as p38 inhibitors, have the potential to ameliorate progression of periodontal disease (23), rheumatic pathologies, and other chronic inflammatory/degenerative disorders. The TLR4 antagonist *B. quintana* LPS (31) has been demonstrated to dramatically improve the evolution of experimental arthritis in the mouse (1). Further studies are warranted in order to exploit the modulation of TLR4 and p38 MAPK in the therapy of chronic inflammatory/degenerative diseases.

**REFERENCES**


effects of *Veillonella parvula* and *Bacteroides intermedius* lipopolysaccharides. Microbiologica 14:315–323.


